Celera Genomics Appoints Paulette Dillon Chief Business Officer
Rockville, MD - March 01, 2004
Celera Genomics Group (NYSE:CRA), an Applera Corporation Business, today announced that Paulette A. Dillon has been appointed Chief Business Officer, reporting to Kathy Ordoņez, President, Celera Genomics.
In this position, Mrs. Dillon will lead strategic business and portfolio planning for the company, as well as business development activities such as licensing and the formation of new collaborations. She will work closely with Robert Booth, Ph.D., Chief Scientific Officer of Celera Genomics, and the other members of Celeras executive team to maintain alignment between business strategies and research and development efforts.
"Our therapeutic discovery programs and Targeted Medicine strategy have advanced to the point where partnerships and licensing are expected to become increasingly important, said Ms. Ordoņez. Paulette possesses a strong combination of pharmaceutical experience and negotiating skills, and has demonstrated the leadership, creativity, and focus necessary to close strategic deals. We look forward to her contributions to Celera.
Mrs. Dillon has over 17 years of diverse business experience gained through a variety of management positions she has held within pharmaceutical and biotech companies. Her experience includes strategic planning, portfolio management, early commercial development, business development, new product planning, marketing and sales. Most recently, Mrs. Dillon was Vice President, Market and Business Development at Exelixis Pharmaceuticals, Inc. In this capacity, she led efforts related to strategic collaborations, new product planning, and in- and out-licensing of therapeutics.
Targeted Medicine integrates the latest genetic and proteomic technologies and pharmacogenomics to identify and validate therapeutic targets, markers of disease, and targeted therapies. It utilizes diagnostics to monitor patient response and to stratify populations for selection of therapy and pharmacogenomics in clinical trials to improve efficacy and safety.
About Celera Genomics and Applera Corporation
Applera Corporation consists of two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics. Its Celera Discovery SystemTM online platform, marketed exclusively by Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2003. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at www.celera.com.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.